课题基金 / 基金详情

ORAL SDZ PSC 833 AND INTRAVENOUS PACLITAXEL IN ADVANCED CANCER

ORAL SDZ PSC 833 AND INTRAVENOUS PACLITAXEL IN ADVANCED CANCER
口服 SDZ PSC 833 和静脉注射紫杉醇治疗晚期癌症
批准号:
6274237
负责人:
PAULA M. FRACASSO
金额:
$2.24万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1997
资助国家:
美国
项目状态:
已结题
起止时间:
1997-12-01 至 1998-11-30

项目摘要

项目成果

PAULA M. FRACASSO的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The development of drug resistance to antineoplastic drugs is a tremendous obstacle to effective treatment of human malignancies. The problem of drug re-sistance is compounded by the emergence of tumors cross-resistant to multiple chemotherapeutic agents related in structure and function to the original selective agent. This phenomenon, termed multidrug resistance, may be caused by a protein, P-glycoprotein, which acts as an ATP-dependent efflux pump reducing the intracellular accumulation of certain antineoplastic agents.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Education and Dissemination of Nanomedicine in Cancer Core (EDNIC)
  • 批准号:
    7738085
  • 项目类别:
  • 资助金额:
    $6.7万
  • 财政年份:
    2008
  • 负责人:
    PAULA M. FRACASSO
  • 依托单位:
An Exploratory Study of UCN-01 and Irinotecan in Advanced Triple Negative Breast
  • 批准号:
    7275903
  • 项目类别:
  • 资助金额:
    $27.84万
  • 财政年份:
    2007
  • 负责人:
    PAULA M. FRACASSO
  • 依托单位:
An Exploratory Study of UCN-01 and Irinotecan in Advanced Triple Negative Breast
  • 批准号:
    7498461
  • 项目类别:
  • 资助金额:
    $26.92万
  • 财政年份:
    2007
  • 负责人:
    PAULA M. FRACASSO
  • 依托单位:
Overcoming Barriers to Early Phase Clinical Trials
  • 批准号:
    6666028
  • 项目类别:
  • 资助金额:
    $12.48万
  • 财政年份:
    2003
  • 负责人:
    PAULA M. FRACASSO
  • 依托单位:
海外基金